Spectrodensitometric determination of clorazepate dipotassium, primidone and chlorzoxazone each in presence of its degradation product

Green Constant-wavelength Concurrent Selective Fluorescence Method for Assay of Ibuprofen and Chlorzoxazone in Presence of Chlorzoxazone Degradation Product

Lower back pain is a universal dilemma leaving a negative effect on both health and life quality. It was found that a fixed dose combination of chlorzoxazone and ibuprofen gave a higher efficiency than analgesic alone in treatment of acute lower back pain. Based on the significant benefit of that combination, a green, sensitive, rapid, direct, and cost-effective method is created for concurrent determination of ibuprofen and chlorzoxazone in presence of 2-amino para chlorophenol (a synthetic precursor and potential impurity of chlorzoxazone) adopting the synchronous spectrofluorimetric technique. Synchronous spectrofluorimetric technique is adopted to avoid the highly overlapped native spectra of both drugs. The synchronous spectrofluorometric method was applied at Δλ = 50 nm, ibuprofen was measured at 227 nm while chlorzoxazone was measured at 282 nm with no hindering from one to another. The various experimental variables affecting the performance of the suggested technique were explored and adjusted. The suggested technique showed good linearity from 0.02 to 0.6 and 0.1 to 5.0 µg/mL for ibuprofen and chlorzoxazone, respectively. The produced detection limits were 0.27 × 10^-3 and 0.03, while the quantitation limits were 0.82 × 10^-3 and 0.09 µg/mL for ibuprofen and chlorzoxazone, respectively. The suggested approach was successfully applied for the analysis of the studied drugs in the synthetic mixture, different pharmaceutical preparations, and spiked human plasma. The suggested technique was validated with respect to the International Council of Harmonization (ICH) recommendations. The suggested technique was found to be simpler and greener with lower cost compared to the earlier reported methods which required complicated techniques, longer time of analysis, and less safe solvents and reagents. Green profile assessment for the developed method compared with the reported spectrofluorometric method was performed using four assessment tools. These tools confirmed that the recommended technique attained the most possible green parameters, so it could be used as a greener option in routine quality control for analyzing the two drugs in genuine form and pharmaceutical preparations.

Validated specific HPLC-DAD method for simultaneous estimation of paracetamol and chlorzoxazone in the presence of five of their degradation products and toxic impurities

This work demonstrates a specific and reliable HPLC with diode array detection (DAD) method for the simultaneous estimation of paracetamol (PAR) and chlorzoxazone (CZ) in the presence of five of their degradation products and toxic impurities; namely; 4-aminophenol (AP), 4-nitrophenol (NP), acetanilide (AT), 4-chloroacetanilide (CA) and 2-amino-4-chlorophenol (ACP). Successful chromatographic separation was accomplished using Waters Symmetry C8 column (3.9 × 150 mm, 5 μm) with gradient elution of the mobile phase consisting of 0.05 M phosphate buffer pH 7.5 and methanol. The gradient elution started with 5% (by volume) methanol ramped up linearly to 50% in 10 min, and then maintained at this percentage afterward till the end of the run. The mobile phase was pumped at a flow rate of 1.0 mL/min. The multiple wavelength detector was adjusted at 244 and 285 nm to quantify PAR and CZ, respectively. Additionally, the wavelength 270 nm was found suitable for monitoring the separation of the entire mixture of PAR, CZ, and their impurities. Seven peaks eluted with excellent resolution at retention times 3.4, 5.7, 8.0, 10.1, 10.8, 13.5, and 14.4 min for AP, PAR, NP, AT, ACP, CZ, and CA, respectively. Performance of the proposed method was validated with respect to linearity, range, precision, accuracy, specificity, robustness, detection, and quantitation limits. Calibration curves were linear in the ranges of 10-75 and 10-100 µg/mL for PAR and CZ, respectively with correlation coefficients not less than 0.9998. The proposed method proved to be specific and stability indicating by the resolution of both drugs from their degradation products and toxic impurities. Validated HPLC method was successfully applied to the analysis of PAR and CZ in their combined capsules dosage form, and assay results were favorably compared with a published reference HPLC method. DAD served as an efficient tool for peak identity and purity verification.